Allievex launches with Pappas cash and rare disease drug from BioMarin
In July 2015, BioMarin began a series of trials for a drug targeting a rare and fatal childhood disease that had remained virtually unchanged since its 1963 discovery. Now, with their lead candidate entering Phase II, they’re handing it off to a new company out of Pappas Capital: Allievex.
Backed by Pappas and Novo Holdings, Allievex will tackle Sanfilippo Syndrome type B, a lysosomal neurological condition for which no treatment exists. Allievex CEO Thomas Mathers indicated to Endpoints News that the new company would broadly focus on childhood conditions but begin with Sanfilippo and the BioMarin treatment:
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
